| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
ProMIS Neurosciences is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSE’s are misfolded regions on otherwise normal proteins. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.
Company News
6/8/2021 – ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer's disease
5/27/2021 – ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
5/25/2021 – ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
5/21/2021 – ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
5/19/2021 – ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
5/14/2021 – ProMIS Neurosciences Announces First Quarter 2021 Results
5/12/2021 – ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
3/31/2021 – ProMIS Neurosciences Announces Fiscal Year 2020 Results
3/22/2021 – ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
© 2021 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
